News & AnalysisAcelyrin gathers $120m Series BAcelyrin, a clinical-stage biopharma company, has raised $250 million in Series B financing.ByIris Dorbian16 November 2021•1 min readJavaScript is required to read this article. Please enable it in your browser and reload the page.DealsHealthcareBriefs